This review highlights percutaneous transluminal septal myocardial ablation as an effective therapeutic option for hypertrophic obstructive cardiomyopathy, leading to gradient reduction and clinical improvement.
May support septal ablation in HOCM unsuitable for surgery; leaves open need for RCTs vs myectomy.
Until the early 1990s, surgical myectomy was the standard treatment for patients with hypertrophic obstructive cardiomyopathy and drug refractory symptoms. In the past few years, the potential therapeutic options have dramatically changed with the introduction of DDD-pacemaker implantation and percutaneous transluminal septal myocardial ablation by alcohol-induced septal branch occlusion. The circumscribed therapeutic myocardial infarction results in widening of the left ventricular outflow tract with consecutive gradient reduction. Follow-up studies show impressive clinical improvement, as well as further gradient reduction as a result of left ventricular remodeling. In this article, we provide an updated review of the latest results of percutaneous transluminal septal myocardial ablation.
No takes yet. Share an insight, caveat, or question.
Seggewiß et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: